Millennium Management
MLYS icon

Millennium Management’s Mineralys Therapeutics MLYS Stock Holding History

Millennium Management’s Portfolio MLYS Stock Details MLYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14.2M Buy
525,260
+446,635
+568% +$13.1M 0.01% 1836
2025
Q4 		$2.85M Sell
78,625
-325,964
-81% -$13.1M ﹤0.01% 3617
2025
Q3 		$15.3M Buy
404,589
+161,020
+66% +$3.48M 0.01% 1959
2025
Q2 		$3.3M Sell
243,569
-181,122
-43% -$2.62M ﹤0.01% 3408
2025
Q1 		$6.74M Sell
424,691
-676,983
-61% -$7.79M ﹤0.01% 2568
2024
Q4 		$13.6M Buy
1,101,674
+1,002,941
+1,016% +$13.1M 0.01% 1877
2024
Q3 		$1.2M Buy
98,733
+33,195
+51% +$402K ﹤0.01% 4125
2024
Q2 		$767K Buy
65,538
+28,198
+76% +$355K ﹤0.01% 4298
2024
Q1 		$482K Sell
37,340
-343,419
-90% -$4.24M ﹤0.01% 4853
2023
Q4 		$3.27M Buy
380,759
+16,416
+5% +$129K ﹤0.01% 3162
2023
Q3 		$3.46M Buy
+364,343
New +$4.75M ﹤0.01% 3061

Other funds holding MLYS

CP
Catalys Pacific Tokyo, Japan $231M AUM 83.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Millennium Management's MLYS Position: Q1 2026 in Review

Millennium Management increased its Mineralys Therapeutics (MLYS) stake by 568% in Q1 2026, buying an estimated $13.1M and bringing the position to 525,260 shares worth $14.2M. The position accounts for 0.01% of the portfolio, ranked #1836.

Millennium Management first reported a position in MLYS in Q3 2023 and has held it in 11 quarters since. The position peaked at $15.3M in Q3 2025. 214 funds tracked by Wall St. Rank hold MLYS as of Q1 2026.

  • Millennium Management held 525,260 shares of Mineralys Therapeutics worth $14.2M as of Q1 2026.
  • Millennium Management bought 446,635 Mineralys Therapeutics shares in Q1 2026, an estimated $13.1M.
  • Mineralys Therapeutics made up 0.01% of Millennium Management's portfolio in Q1 2026, its #1836 holding.
  • Millennium Management first reported a position in Mineralys Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • Millennium Management's Mineralys Therapeutics position peaked at $15.3M in Q3 2025.
  • 214 funds tracked by Wall St. Rank held Mineralys Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.